# EDGAR Filing Document

**Accession Number:** 0001905495
**File Stem:** 0000000000-23-000605
**Filing Date:** 2023-1
**Character Count:** 4193
**Document Hash:** cd5c213c7023a5bab842ff306f8a4651
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000605.hdr.sgml**: 20230628

**ACCESSION NUMBER**: 0000000000-23-000605

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230119

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CancerVAX, Inc.
- **CENTRAL INDEX KEY:** 0001905495
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862876870
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 351 PASEO NUEVO, FLOOR 2
- **CITY:** SANTA BARBARA
- **STATE:** CA
- **ZIP:** 93101
- **BUSINESS PHONE:** (804) 356-1810

**MAIL ADDRESS:**
- **STREET 1:** 351 PASEO NUEVO, FLOOR 2
- **CITY:** SANTA BARBARA
- **STATE:** CA
- **ZIP:** 93101
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-23-001219

## Text-Extract

```

United States securities and exchange commission logo

                              January 19, 2023

       Ryan Davies
       Chief Executive Officer
       CancerVAX, Inc.
       351 Paseo Nuevo, Floor 2
       Santa Barbara, CA 93101

                                                        Re: CancerVAX, Inc.
                                                            Offering Statement
on Form 1-A
                                                            Filed January 12,
2023
                                                            File No. 024-12130

       Dear Ryan Davies:

              We have reviewed your offering statement and have the following
comment. In our
       comment, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to this letter by amending your offering statement
and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response. After reviewing any amendment to your offering statement and
the information you
       provide in response to this comment, we may have additional comments.

       Offering Statement on Form 1-A

       Part I
       Item 3. Application of Rule 262, page i

   1.                                                   In Item 3 of Part I, we
note that you have checked the box that "bad actor" disclosure
                                                        under Rule 262(d) is
provided in Part II of the offering statement; however, we could not
                                                        locate such disclosure.
Please provide the appropriate disclosure in Part II or correct the
                                                        check box in Part I.
               We will consider qualifying your offering statement at your
request. If a participant in
       your offering is required to clear its compensation arrangements with
FINRA, please have
       FINRA advise us that it has no objections to the compensation
arrangements prior to
       qualification.
 Ryan Davies
CancerVAX, Inc.
January 19, 2023
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff. We also remind you that, following qualification of your
Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a
Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered
by the report.

       Please contact Arzhang Navai at 202-551-4676 or Laura Crotty at
202-551-7614 with any
questions.

                                                           Sincerely,
FirstName LastNameRyan Davies
                                                           Division of
Corporation Finance
Comapany NameCancerVAX, Inc.
                                                           Office of Life
Sciences
January 19, 2023 Page 2
cc:       Callie Jones
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._